{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=43", "query": { "intervention": "Neoadjuvant therapy", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 2085, "total_pages": 209, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=44&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=42&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T14:49:20.860Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05894239", "title": "A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Inavolisib", "type": "DRUG" }, { "name": "Phesgo", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Taxane-based Chemotherapy", "type": "DRUG" }, { "name": "Optional Endocrine Therapy of Investigator's Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2023-09-08", "completion_date": "2032-12-28", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-11-09T14:49:20.860Z", "location_count": 20, "location_summary": "Gilbert, Arizona • Burbank, California • Corona, California + 17 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05894239" }, { "nct_id": "NCT07829471", "title": "Impact of Routine Electronic Patient-Reported Outcome (ePRO)Symptom Monitoring During Neoadjuvant Therapy in Patients withPancreatic Adenocarcinoma on Patient Experience and ClinicalOutcomes: A Prospective Pre-Post Implementation Study", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "ePRO", "Symptom Monitoring", "Neoadjuvant Therapy", "Pancreatic Adenocarcinoma", "Clinical Outcomes" ], "interventions": [ { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2027-02-21", "completion_date": "2032-07-01", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-11-09T14:49:20.860Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07829471" }, { "nct_id": "NCT01261728", "title": "Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Gemcitabine and Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2010-12-14", "completion_date": "2025-08-06", "has_results": true, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-11-09T14:49:20.860Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Hartford, Connecticut • Basking Ridge, New Jersey + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01261728" }, { "nct_id": "NCT02115607", "title": "Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Definity infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 17, "start_date": "2014-03", "completion_date": "2018-05-23", "has_results": true, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-11-09T14:49:20.860Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02115607" }, { "nct_id": "NCT06044311", "title": "Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma Esophagus", "Locally Advanced Adenocarcinoma", "Siewert Type I Adenocarcinoma of Esophagogastric Junction", "Siewert Type II Adenocarcinoma of Esophagogastric Junction" ], "interventions": [ { "name": "Vactosertib", "type": "DRUG" }, { "name": "Standard of Care Preoperative Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Melissa Lumish", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2024-09-30", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-09T14:49:20.860Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06044311" }, { "nct_id": "NCT00572728", "title": "Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "CT", "type": "PROCEDURE" }, { "name": "18F-FLT", "type": "DRUG" }, { "name": "PET", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2008-12", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-12-30", "last_synced_at": "2026-11-09T14:49:20.860Z", "location_count": 27, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Dunedin", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00572728" }, { "nct_id": "NCT05219695", "title": "Medical Imaging and Focused Ultrasound Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fibroadenoma", "Breast Cancer Stage I" ], "interventions": [ { "name": "Harmonic motion imaging guided focused ultrasound (HMIgFUS)", "type": "PROCEDURE" }, { "name": "Microbubble-mediated Low Intensity Focused Ultrasound (LIFU)", "type": "PROCEDURE" }, { "name": "Microbubbles", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 82, "start_date": "2022-01-19", "completion_date": "2031-05", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-11-09T14:49:20.860Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05219695" }, { "nct_id": "NCT01220128", "title": "Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Aromatase inhibitor", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Carboplatin AUC", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2011-04-11", "completion_date": "2014-11-14", "has_results": true, "last_update_posted_date": "2021-05-25", "last_synced_at": "2026-11-09T14:49:20.860Z", "location_count": 8, "location_summary": "Newark, Delaware • Plantation, Florida • Boston, Massachusetts + 5 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Plantation", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Bend", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01220128" }, { "nct_id": "NCT02287233", "title": "A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "AML" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 94, "start_date": "2014-12-31", "completion_date": "2021-08-10", "has_results": true, "last_update_posted_date": "2022-08-29", "last_synced_at": "2026-11-09T14:49:20.860Z", "location_count": 5, "location_summary": "Kansas City, Kansas • New York, New York • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02287233" }, { "nct_id": "NCT05312710", "title": "Safety and Efficacy of APG-157 in Head and Neck Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Squamous Cell Carcinoma of Oral Cavity", "Squamous Cell Carcinoma of the Oropharynx" ], "interventions": [ { "name": "APG-157", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aveta Biomics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-04-22", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-11-09T14:49:20.860Z", "location_count": 2, "location_summary": "Los Angeles, California • Miami, Florida", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05312710" } ] }